News in Numbers

Eli Lilly has chosen Pennsylvania to house a new $3.5bn manufacturing facility that will produce a forthcoming wave of new weight loss therapies.

The World Health Organization (WHO) has highlighted that more than one billion people worldwide are living with Neglected Tropical Diseases (NTDs) and continue to suffer due to discrimination, social stigma and untreated mental health conditions.

This year, sales of Bristol Myers Squibb’s (BMS) and Pfizer’s drug Eliquis (apixaban) are projected to decline by 15.2% due to the loss of its European market exclusivity on 19 May 2026.

The recent arrival of the oral appetite suppressant drug Wegovy across 70,000 US pharmacies offers a more affordable and convenient weight-loss treatment option than injectable Wegovy or Eli Lilly’s (US) once-weekly injectable GLP-1 medicine Zepbound. 

In the UK, GlobalData epidemiologists forecast that diagnosed incident cases of influenza-like illness will be 1.44 million cases, whereas 50,000 cases will be hospitalised in 2026.